A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

NCT01785771 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

100

Enrollment

INDUSTRY

Sponsor class

Stopped Decision by Sponsor

Conditions

Type 2 Diabetes

Interventions

DRUG: ITCA 650 (exenatide in DUROS)

Sponsor

Intarcia Therapeutics